Protective mechanisms against the antitumor agent bleomycin: Lessons from Saccharomyces cerevisiae

Dindial Ramotar; Huijie Wang

doi:10.1007/s00294-003-0396-1

Protective mechanisms against the antitumor agent bleomycin: Lessons from Saccharomyces cerevisiae

Dindial Ramotar^*, Huijie Wang

^*Corresponding author for this work

University of Montreal

Research output: Contribution to journal › Review article › peer-review

52 Citations (Scopus)

Abstract

Bleomycin is a small glycopeptide antibiotic used in combination therapy for the treatment of a few types of human cancer. The antitumor effect of bleomycin is most likely caused by its ability to bind to DNA and induce the formation of toxic DNA lesions via a free radical reactive (Fe.bleomycin) complex. However, the chemotherapeutic potential of bleomycin is limited, as it causes pulmonary fibrosis and tumor resistance at high doses. The chemical structure and modes of action of bleomycin have been extensively studied and these provide a foundation towards improving the therapeutic value of the drug. This review provides a first account of the current state of knowledge of the cellular processes that can allow the yeast Saccharomyces cerevisiae to evade the lethal effects of bleomycin. This model organism is likely to provide rapid clues in our understanding of bleomycin resistance in tumor cells.

Original language	English
Pages (from-to)	213-224
Number of pages	12
Journal	Current Genetics
Volume	43
Issue number	4
DOIs	https://doi.org/10.1007/s00294-003-0396-1
Publication status	Published - 1 Jul 2003
Externally published	Yes

Keywords

Bleomycin
DNA damage
Drug sensitivity
Repair enzymes
Yeast

Access to Document

10.1007/s00294-003-0396-1

Cite this

@article{10a2d31ac4f74148a7f13ccf671b52c1,

title = "Protective mechanisms against the antitumor agent bleomycin: Lessons from Saccharomyces cerevisiae",

abstract = "Bleomycin is a small glycopeptide antibiotic used in combination therapy for the treatment of a few types of human cancer. The antitumor effect of bleomycin is most likely caused by its ability to bind to DNA and induce the formation of toxic DNA lesions via a free radical reactive (Fe.bleomycin) complex. However, the chemotherapeutic potential of bleomycin is limited, as it causes pulmonary fibrosis and tumor resistance at high doses. The chemical structure and modes of action of bleomycin have been extensively studied and these provide a foundation towards improving the therapeutic value of the drug. This review provides a first account of the current state of knowledge of the cellular processes that can allow the yeast Saccharomyces cerevisiae to evade the lethal effects of bleomycin. This model organism is likely to provide rapid clues in our understanding of bleomycin resistance in tumor cells.",

keywords = "Bleomycin, DNA damage, Drug sensitivity, Repair enzymes, Yeast",

author = "Dindial Ramotar and Huijie Wang",

year = "2003",

month = jul,

day = "1",

doi = "10.1007/s00294-003-0396-1",

language = "English",

volume = "43",

pages = "213--224",

journal = "Current Genetics",

issn = "0172-8083",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "4",

}

TY - JOUR

T1 - Protective mechanisms against the antitumor agent bleomycin

T2 - Lessons from Saccharomyces cerevisiae

AU - Ramotar, Dindial

AU - Wang, Huijie

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Bleomycin is a small glycopeptide antibiotic used in combination therapy for the treatment of a few types of human cancer. The antitumor effect of bleomycin is most likely caused by its ability to bind to DNA and induce the formation of toxic DNA lesions via a free radical reactive (Fe.bleomycin) complex. However, the chemotherapeutic potential of bleomycin is limited, as it causes pulmonary fibrosis and tumor resistance at high doses. The chemical structure and modes of action of bleomycin have been extensively studied and these provide a foundation towards improving the therapeutic value of the drug. This review provides a first account of the current state of knowledge of the cellular processes that can allow the yeast Saccharomyces cerevisiae to evade the lethal effects of bleomycin. This model organism is likely to provide rapid clues in our understanding of bleomycin resistance in tumor cells.

AB - Bleomycin is a small glycopeptide antibiotic used in combination therapy for the treatment of a few types of human cancer. The antitumor effect of bleomycin is most likely caused by its ability to bind to DNA and induce the formation of toxic DNA lesions via a free radical reactive (Fe.bleomycin) complex. However, the chemotherapeutic potential of bleomycin is limited, as it causes pulmonary fibrosis and tumor resistance at high doses. The chemical structure and modes of action of bleomycin have been extensively studied and these provide a foundation towards improving the therapeutic value of the drug. This review provides a first account of the current state of knowledge of the cellular processes that can allow the yeast Saccharomyces cerevisiae to evade the lethal effects of bleomycin. This model organism is likely to provide rapid clues in our understanding of bleomycin resistance in tumor cells.

KW - Bleomycin

KW - DNA damage

KW - Drug sensitivity

KW - Repair enzymes

KW - Yeast

UR - http://www.scopus.com/inward/record.url?scp=0038495946&partnerID=8YFLogxK

U2 - 10.1007/s00294-003-0396-1

DO - 10.1007/s00294-003-0396-1

M3 - Review article

C2 - 12698269

AN - SCOPUS:0038495946

SN - 0172-8083

VL - 43

SP - 213

EP - 224

JO - Current Genetics

JF - Current Genetics

IS - 4

ER -

Protective mechanisms against the antitumor agent bleomycin: Lessons from Saccharomyces cerevisiae

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this